diagnosis and treatment of valvular heart...

68
Computed Tomography - From basics to clinical use Diagnosis and Treatment of Valvular Heart Disease David Messika-Zeitoun

Upload: truongnga

Post on 20-May-2018

216 views

Category:

Documents


2 download

TRANSCRIPT

Page 1: Diagnosis and treatment of valvular heart disease.assets.escardio.org/assets/presentations/EE2012/48.pdfDiagnosis and Treatment of Valvular Heart Disease David Messika-Zeitoun Disclosures

Computed Tomography - From basics to

clinical use

Diagnosis and Treatment of

Valvular Heart Disease

David Messika-Zeitoun

Page 2: Diagnosis and treatment of valvular heart disease.assets.escardio.org/assets/presentations/EE2012/48.pdfDiagnosis and Treatment of Valvular Heart Disease David Messika-Zeitoun Disclosures

Disclosures

Lectures fees for Edwards, Abbott

Consultant fees from Symetis

Page 3: Diagnosis and treatment of valvular heart disease.assets.escardio.org/assets/presentations/EE2012/48.pdfDiagnosis and Treatment of Valvular Heart Disease David Messika-Zeitoun Disclosures

You know what?

Echo is tough …

Page 4: Diagnosis and treatment of valvular heart disease.assets.escardio.org/assets/presentations/EE2012/48.pdfDiagnosis and Treatment of Valvular Heart Disease David Messika-Zeitoun Disclosures

Planimetry

Page 5: Diagnosis and treatment of valvular heart disease.assets.escardio.org/assets/presentations/EE2012/48.pdfDiagnosis and Treatment of Valvular Heart Disease David Messika-Zeitoun Disclosures

Transoephageal Echocardiography

TEE

Page 6: Diagnosis and treatment of valvular heart disease.assets.escardio.org/assets/presentations/EE2012/48.pdfDiagnosis and Treatment of Valvular Heart Disease David Messika-Zeitoun Disclosures

Computed Tomography Planimetry

CT scan

Iodine contrast agent

ECG-gating

Mid-late systolic image

reconstruction

Page 7: Diagnosis and treatment of valvular heart disease.assets.escardio.org/assets/presentations/EE2012/48.pdfDiagnosis and Treatment of Valvular Heart Disease David Messika-Zeitoun Disclosures

Example of Planimetry of the Aortic Valve Area

Laissy, Heart 2007

Page 8: Diagnosis and treatment of valvular heart disease.assets.escardio.org/assets/presentations/EE2012/48.pdfDiagnosis and Treatment of Valvular Heart Disease David Messika-Zeitoun Disclosures

Aortic Valve Area

Feuchtner, JACC 2006

Page 9: Diagnosis and treatment of valvular heart disease.assets.escardio.org/assets/presentations/EE2012/48.pdfDiagnosis and Treatment of Valvular Heart Disease David Messika-Zeitoun Disclosures

Planimetry of Aortic Valve Area

AV

A-M

DC

T (

cm

2)

AVA-Echocardiography (cm2)

0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1 1.1 1.2 1.3 1.4

0.2

0.3

0.4

0.5

0.6

0.7

0.8

0.9

1

1.1

1.2

1.3

1.4

1.5

-0.8

-0.6

-0.4

-0.2

0.0

0.2

0.4

0.6

0.8

0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 1.1 1.2 1.3 1.4

Dif

fere

nc

e (

AV

A-M

DC

T,

AV

A-E

ch

oca

rdio

gra

ph

y )

(cm

2)

Mean (AVA-MDCT, AVA-Echocardiography ) (cm2)

Laissy, Heart 2007

Page 10: Diagnosis and treatment of valvular heart disease.assets.escardio.org/assets/presentations/EE2012/48.pdfDiagnosis and Treatment of Valvular Heart Disease David Messika-Zeitoun Disclosures

Aortic Valve Area - Results

N AVA echo

(cm2)

AVA CT

(cm2)

Correlation

Coefficient

SD of the

difference (cm2)

Feuchtner 30 0.90±0.22

0.6 – 1.7

0.94±0.27

0.6 – 1.7

0.89 0.13

Bouvier 30 0.80±0.27 0.87±0.33 - 0.16

Alkadhi 20 0.83±0.33

0.4 – 1.6

0.89±0.35

0.44 – 1.53

0.95 0.10

Laissy 40 0.81±0.20

0.35 - 1.2

0.87±0.23

0.40 - 1.45

0.77 0.15

Pouleur 48 2.0±1.5

0.5 – 6.1

2.5±1.7

0.5 – 6.3

0.96 0.5

Lembecke 36 0.74±0.28

0.3 – 1.6

0.88±0.39

0.3 – 2.0

0.91 0.18

<

Page 11: Diagnosis and treatment of valvular heart disease.assets.escardio.org/assets/presentations/EE2012/48.pdfDiagnosis and Treatment of Valvular Heart Disease David Messika-Zeitoun Disclosures

Aortic Valve Area - Results

36 patients with AS

CT = 0.88±0.39 cm²

TEE = 0.94 ± 0.41 cm²

TTE = 0.74 ± 0.28 cm²

CATH = 0.75 ± 0.31 cm²

Lembcke 2009 Invest Radiol

Effective area

Anatomic area

Page 12: Diagnosis and treatment of valvular heart disease.assets.escardio.org/assets/presentations/EE2012/48.pdfDiagnosis and Treatment of Valvular Heart Disease David Messika-Zeitoun Disclosures

Aortic Valve

Calcifications

Page 13: Diagnosis and treatment of valvular heart disease.assets.escardio.org/assets/presentations/EE2012/48.pdfDiagnosis and Treatment of Valvular Heart Disease David Messika-Zeitoun Disclosures

Aortic Valve Calcification (AVC)

Aortic valve calcification (AVC) Coronary artery calcification (AVC)

CT is ideally suited to objectively

and quantitatively assessed calcifications

Page 14: Diagnosis and treatment of valvular heart disease.assets.escardio.org/assets/presentations/EE2012/48.pdfDiagnosis and Treatment of Valvular Heart Disease David Messika-Zeitoun Disclosures

CT scanner - Acquisition

Forty 3-mm-thick contiguous

transverse slices with 3-mm

table incrementation

Covering the ascending aorta

to the apex

Acquisition triggered by

electrocardiography at 80% of

the RR interval (prospective

ECG-gating)

2 independent runs

No contrast agent

Page 15: Diagnosis and treatment of valvular heart disease.assets.escardio.org/assets/presentations/EE2012/48.pdfDiagnosis and Treatment of Valvular Heart Disease David Messika-Zeitoun Disclosures

CT Scanner – Measurements of Calcifications

Automated

operator-

independent

image-processing

software

Calcification are

defined as 4

adjacent pixels

with density 130

Hounsfield units

Radiologist affect

the selected area

to the coronary

arteries, the aortic

valve….

Page 16: Diagnosis and treatment of valvular heart disease.assets.escardio.org/assets/presentations/EE2012/48.pdfDiagnosis and Treatment of Valvular Heart Disease David Messika-Zeitoun Disclosures

The Agatston Score

For each region of interrest, score = density score * area

Total score: sum of score of each region of interest in all

slices

Hn X Factor

130-199 1

200-299 2

300-399 3

> 400 4

Peak density score

Area 1 = 15 mm²

Peak CT = 350 Hn

Area 1 = 30 mm²

Peak CT = 500 Hn

Region 1. Score = 15 * 3 = 45

Region 2. Score = 30 * 4 = 120

Page 17: Diagnosis and treatment of valvular heart disease.assets.escardio.org/assets/presentations/EE2012/48.pdfDiagnosis and Treatment of Valvular Heart Disease David Messika-Zeitoun Disclosures

Definition of AVC

Aortic valve

calcifications are

defined as

calcifications within

valve leaflets, aortic

annulus, or aortic wall

immediately adjacent

to leaflet or annular

calcification.

Page 18: Diagnosis and treatment of valvular heart disease.assets.escardio.org/assets/presentations/EE2012/48.pdfDiagnosis and Treatment of Valvular Heart Disease David Messika-Zeitoun Disclosures

Examples of degree of AVC

Mild AVC. Score = 200 AU Moderate AVC. score = 800

Severe AVC. Score = 2000

LA

LV

RV

RA

RA

RV

LA

LV

Mitral

Valve

RV

RA

LA

LV

Page 19: Diagnosis and treatment of valvular heart disease.assets.escardio.org/assets/presentations/EE2012/48.pdfDiagnosis and Treatment of Valvular Heart Disease David Messika-Zeitoun Disclosures

EB

CT

(s

co

re)

Weight calcium (mg)

0

1000

2000

3000

4000

5000

0 500 1000 1500 2000 2500 3000 3500

r=0.96, p <0.0001

Anatomic validation for AVC

30 valves specimen

Quantification AVC

EBCT (Agatston score)

Tissue digestion

Page 20: Diagnosis and treatment of valvular heart disease.assets.escardio.org/assets/presentations/EE2012/48.pdfDiagnosis and Treatment of Valvular Heart Disease David Messika-Zeitoun Disclosures

Echocardiographic Evaluation of Aortic Valve Calcifications

None

Mild: isolated spots

Moderate: Multiples

spots

Severe : Large and

diffuse calcifications

Page 21: Diagnosis and treatment of valvular heart disease.assets.escardio.org/assets/presentations/EE2012/48.pdfDiagnosis and Treatment of Valvular Heart Disease David Messika-Zeitoun Disclosures

Echocardiographic Evaluation of Aortic Valve Calcifications

%

0

10

20

30

40

50

60

70

-1 class Identical +1 class

Classification subjective and inaccurate

Page 22: Diagnosis and treatment of valvular heart disease.assets.escardio.org/assets/presentations/EE2012/48.pdfDiagnosis and Treatment of Valvular Heart Disease David Messika-Zeitoun Disclosures

(A) Mild calcification of the left coronary cusp (Volume 74 mm3, aortic valve area 2.4 cm²).

(B) Severe calcification (Volume 5044 mm3, aortic valve area 0.4 cm²)

Page 23: Diagnosis and treatment of valvular heart disease.assets.escardio.org/assets/presentations/EE2012/48.pdfDiagnosis and Treatment of Valvular Heart Disease David Messika-Zeitoun Disclosures

Ao

rtic

va

lve

are

a, cm

2

EBCT Score

0.0

0.5

1.0

1.5

2.0

2.5

3.0

3.5

4.0

4.5

0 1000 2000 3000 4000 5000 6000 7000 8000

R=-0.79, p<0.0001 R=0.86, p<0.0001

Pe

ak

ao

rtic

va

lve

ve

loc

ity,

m/s

ec

EBCT Score

0 1000 2000 3000 4000 5000 6000 7000 8000 0

1

2

3

4

5

6

7

AVC and Hemodynamic Severity

Messika-Zeitoun Circulation 2004

Page 24: Diagnosis and treatment of valvular heart disease.assets.escardio.org/assets/presentations/EE2012/48.pdfDiagnosis and Treatment of Valvular Heart Disease David Messika-Zeitoun Disclosures

EBCT Thresholds S

en

sit

ivit

y

1 - Specificity

0.00

0.10

0.20

0.30

0.40

0.50

0.60

0.70

0.80

0.90

1.00

.00 .10 .20 .30 .40 .50 .60 .70 .80 .90 1.00

Score = 500

AUC=0.89

Score = 1100

Score = 2000

Page 25: Diagnosis and treatment of valvular heart disease.assets.escardio.org/assets/presentations/EE2012/48.pdfDiagnosis and Treatment of Valvular Heart Disease David Messika-Zeitoun Disclosures

Volumetric Assessment

Morghan-Hughes Heart 2003

Page 26: Diagnosis and treatment of valvular heart disease.assets.escardio.org/assets/presentations/EE2012/48.pdfDiagnosis and Treatment of Valvular Heart Disease David Messika-Zeitoun Disclosures

EBCT = MSCT ?

Page 27: Diagnosis and treatment of valvular heart disease.assets.escardio.org/assets/presentations/EE2012/48.pdfDiagnosis and Treatment of Valvular Heart Disease David Messika-Zeitoun Disclosures
Page 28: Diagnosis and treatment of valvular heart disease.assets.escardio.org/assets/presentations/EE2012/48.pdfDiagnosis and Treatment of Valvular Heart Disease David Messika-Zeitoun Disclosures

0.5

1

1.5

2

2.5

3 A

bso

lute

AV

A

0 1000 3000 5000 7000 9000 AVC

0.1

0,.3

0.5

0.7

0.9

1.1

1.3

1.5

Ad

just

ed A

VA

0 1000 3000 5000 7000 9000

AVC

0 10 20 30 40 50 60 70 80 90

100 110 120

Mea

n g

rad

ien

t

0 1000 3000 5000 7000 9000

AVC

0

100

200

300

400

500

600

700

Pea

k v

elo

city

0 1000 3000 5000 7000 9000

AVC Cueff Heart 2011

Page 29: Diagnosis and treatment of valvular heart disease.assets.escardio.org/assets/presentations/EE2012/48.pdfDiagnosis and Treatment of Valvular Heart Disease David Messika-Zeitoun Disclosures

Sen

sib

ilit

y

0,00

0,10

0,20

0,30

0,40

0,50

0,60

0,70

0,80

0,90

1,00

0,00 0,20 0,40 0,60 0,80 1,00

1-Specificity

Sen

sib

ilit

y

0,00

0,10

0,20

0,30

0,40

0,50

0,60

0,70

0,80

0,90

1,00

0,00 0,20 0,40 0,60 0,80 1,00

1-Specificity

Sen

sib

ilit

y

0,00

0,10

0,20

0,30

0,40

0,50

0,60

0,70

0,80

0,90

1,00

0,00 0,20 0,40 0,60 0,80 1,00

1-Specificity

Sen

sib

ilit

y

0,00

0,10

0,20

0,30

0,40

0,50

0,60

0,70

0,80

0,90

1,00

0,00 0,20 0,40 0,60 0,80 1,00

1-Specificity

AVA : AUC=0.86 AVAi : AUC=0.9

MPG: AUC=0.92 MPV : AUC=0.9

700 AU

1651 AU

2000 AU

2000 AU

1651 AU

2000 AU

1651 AU

2000 AU

1651 AU

700 AU

700 AU

700 AU

Page 30: Diagnosis and treatment of valvular heart disease.assets.escardio.org/assets/presentations/EE2012/48.pdfDiagnosis and Treatment of Valvular Heart Disease David Messika-Zeitoun Disclosures

Scanner MSCT Thresholds

Calcium

Score

Sensitivity, % Specificity, % PPV, % NPV, %

500 100 31 46 100

700 98 49 49 98

1000 94 65 55 94

1200 91 65 59 92

1651 82 80 70 88

2000 62 86 72 79

3000 57 91 74 72

Page 31: Diagnosis and treatment of valvular heart disease.assets.escardio.org/assets/presentations/EE2012/48.pdfDiagnosis and Treatment of Valvular Heart Disease David Messika-Zeitoun Disclosures

Clinical Implications

Discrepancies between symptoms

and echocardiographic measurements

Poor echogenicity

Low gradient – low output

Page 32: Diagnosis and treatment of valvular heart disease.assets.escardio.org/assets/presentations/EE2012/48.pdfDiagnosis and Treatment of Valvular Heart Disease David Messika-Zeitoun Disclosures

Contractile reserve

Final AVA < 1 cm2

AVA increase < 0.3 cm2

Dobutamine

up to 20 μg/kg/min

Contractile reserve

Final AVA > 1 cm2

AVA increase 0.3 cm2

No contractile reserve

(SV increase < 20%)

Severe AS Pseudo-severe AS Non conclusive test

Monin Circulation; 108: 319-324

Low Gradient – Low Output

Page 33: Diagnosis and treatment of valvular heart disease.assets.escardio.org/assets/presentations/EE2012/48.pdfDiagnosis and Treatment of Valvular Heart Disease David Messika-Zeitoun Disclosures

47 patients with Low EF

EF ≤ 40%

47 patients

MG > 40 mmHg

AVA < 1 cm²

Severe AS

24 patients

MG ≤ 40 mmHg

AVA < 1 cm²

Low gradient / Low Output

20 patients

Severe AS

14 patients

Non Conclusive AS

2 patient

Pseudo Severe AS

4 patients

MG ≤ 40mmHg

AVA ≥ 1 cm²

Non Severe AS

5 patients

Cueff Heart 2011

Page 34: Diagnosis and treatment of valvular heart disease.assets.escardio.org/assets/presentations/EE2012/48.pdfDiagnosis and Treatment of Valvular Heart Disease David Messika-Zeitoun Disclosures

Koos Radiology 2006

Page 35: Diagnosis and treatment of valvular heart disease.assets.escardio.org/assets/presentations/EE2012/48.pdfDiagnosis and Treatment of Valvular Heart Disease David Messika-Zeitoun Disclosures

Prognostic value of AVC Echocardiographic assessment

Eve

nt

fre

e s

urv

iva

l (%

) No or mild calcification

Moderate or severe

calcification

P<0.0001

0

20

40

60

80

100

0 1 2 3 4 5 Years Rosenhek NEJM 2000

Page 36: Diagnosis and treatment of valvular heart disease.assets.escardio.org/assets/presentations/EE2012/48.pdfDiagnosis and Treatment of Valvular Heart Disease David Messika-Zeitoun Disclosures

Prognostic value of AVC EBCT assessment

AVC < 500 AU

AVC 500 AU

P=0.0002

0

20

40

60

80

100

0 1 2 3 4 5

Eve

nt

fre

e s

urv

iva

l (%

)

Years Messika-Zeitoun Circulation 2004

AVC and hemodynamic severity provide

complementary prognostic information

Page 37: Diagnosis and treatment of valvular heart disease.assets.escardio.org/assets/presentations/EE2012/48.pdfDiagnosis and Treatment of Valvular Heart Disease David Messika-Zeitoun Disclosures

Ao

rtic

va

lve

are

a, cm

2

EBCT Score

0.0

0.5

1.0

1.5

2.0

2.5

3.0

3.5

4.0

4.5

0 1000 2000 3000 4000 5000 6000 7000 8000

R=-0.79, p<0.0001 R=0.86, p<0.0001

Pe

ak

ao

rtic

va

lve

ve

loc

ity,

m/s

ec

EBCT Score

0 1000 2000 3000 4000 5000 6000 7000 8000 0

1

2

3

4

5

6

7

AVC and Hemodynamic Severity are Not Equivalent

Messika-Zeitoun Circulation 2004

Page 38: Diagnosis and treatment of valvular heart disease.assets.escardio.org/assets/presentations/EE2012/48.pdfDiagnosis and Treatment of Valvular Heart Disease David Messika-Zeitoun Disclosures

Valve Anatomy

Page 39: Diagnosis and treatment of valvular heart disease.assets.escardio.org/assets/presentations/EE2012/48.pdfDiagnosis and Treatment of Valvular Heart Disease David Messika-Zeitoun Disclosures

Scanner Bicuspid vs. Tricuspid

Alkhadi, Radiology 2006 Bouvier, EHJ 2006

Page 40: Diagnosis and treatment of valvular heart disease.assets.escardio.org/assets/presentations/EE2012/48.pdfDiagnosis and Treatment of Valvular Heart Disease David Messika-Zeitoun Disclosures

Transcatheter

Aortic Valve

Implantation (TAVI)

Page 41: Diagnosis and treatment of valvular heart disease.assets.escardio.org/assets/presentations/EE2012/48.pdfDiagnosis and Treatment of Valvular Heart Disease David Messika-Zeitoun Disclosures

Vascular Access

Page 42: Diagnosis and treatment of valvular heart disease.assets.escardio.org/assets/presentations/EE2012/48.pdfDiagnosis and Treatment of Valvular Heart Disease David Messika-Zeitoun Disclosures

Safety Issue

Page 43: Diagnosis and treatment of valvular heart disease.assets.escardio.org/assets/presentations/EE2012/48.pdfDiagnosis and Treatment of Valvular Heart Disease David Messika-Zeitoun Disclosures

The Aortic Annulus is not a Ring …

Anderson Multimedia Manual of Cardiothoracic Surgery 2006

Page 44: Diagnosis and treatment of valvular heart disease.assets.escardio.org/assets/presentations/EE2012/48.pdfDiagnosis and Treatment of Valvular Heart Disease David Messika-Zeitoun Disclosures
Page 45: Diagnosis and treatment of valvular heart disease.assets.escardio.org/assets/presentations/EE2012/48.pdfDiagnosis and Treatment of Valvular Heart Disease David Messika-Zeitoun Disclosures

Ovale Shape

Coronal view: 26±3 mm Sagittal view : 24±3 mm

Page 46: Diagnosis and treatment of valvular heart disease.assets.escardio.org/assets/presentations/EE2012/48.pdfDiagnosis and Treatment of Valvular Heart Disease David Messika-Zeitoun Disclosures

Aorta

Left atrium

A

C

B D

Page 47: Diagnosis and treatment of valvular heart disease.assets.escardio.org/assets/presentations/EE2012/48.pdfDiagnosis and Treatment of Valvular Heart Disease David Messika-Zeitoun Disclosures

Annulus

Diameter

vs. TTE vs. TEE

P R P R

ECHOCARDIOGRAPHY

TTE 23.9±2.1 - - 0.13 0.89

TEE 24.1±2.1 0.13 0.89 - -

CT

PLAN BASAL

Long axis 27.5±3.1 <0.0001 0.69 <0.0001 0.67

Short axis 21.7±2.3 <0.0001 0.73 <0.0001 0.69

Mean 24.6±2.4 0.004 0.80 0.07 0.77

3 CAVITY 23.8±2.6 0.73 0.71 0.26 0.70

Page 48: Diagnosis and treatment of valvular heart disease.assets.escardio.org/assets/presentations/EE2012/48.pdfDiagnosis and Treatment of Valvular Heart Disease David Messika-Zeitoun Disclosures

Implantation Strategy

Aortic annulus diameter

18 21 25

23 mm Prosthesis 26 mm Prosthesis

Page 49: Diagnosis and treatment of valvular heart disease.assets.escardio.org/assets/presentations/EE2012/48.pdfDiagnosis and Treatment of Valvular Heart Disease David Messika-Zeitoun Disclosures

Strategy of implantation Agreement

with TTE

Agreement

with TEE

23 mm

Prosthesis

26 mm

Prosthesis

No

implantation

% Kappa % Kappa

Echography

TTE 5 29 11 - - 83% 0.68

TEE 6 25 14 83% 0.68 - -

CT

BASAL

Long axis 0 10 35 36% 0.03 42% 0.07

Short axis 16 21 8 47% 0.13 42% 0.09

Mean 4 24 17 62% 0.32 62% 0.34

3 CAVITY 7 25 13 60% 0.28 58% 0.27

Page 50: Diagnosis and treatment of valvular heart disease.assets.escardio.org/assets/presentations/EE2012/48.pdfDiagnosis and Treatment of Valvular Heart Disease David Messika-Zeitoun Disclosures
Page 51: Diagnosis and treatment of valvular heart disease.assets.escardio.org/assets/presentations/EE2012/48.pdfDiagnosis and Treatment of Valvular Heart Disease David Messika-Zeitoun Disclosures

Comprehensive

Evaluation

of AS

Page 52: Diagnosis and treatment of valvular heart disease.assets.escardio.org/assets/presentations/EE2012/48.pdfDiagnosis and Treatment of Valvular Heart Disease David Messika-Zeitoun Disclosures

CT Coronary Angiography

Mollet JACC 2004

Page 53: Diagnosis and treatment of valvular heart disease.assets.escardio.org/assets/presentations/EE2012/48.pdfDiagnosis and Treatment of Valvular Heart Disease David Messika-Zeitoun Disclosures

CT Coronary Angiography in AS

Gilard Reant Laissy

N of patients 55 40 40

Prevalence of coronary stenosis

(coronary angiogram)

20 32.5 33

Sensibility, % 100 85 85

Specificity, % 80 78 93

Positive predictive value, % 55 67 85

Negative predictive value, % 100 96 93

Page 54: Diagnosis and treatment of valvular heart disease.assets.escardio.org/assets/presentations/EE2012/48.pdfDiagnosis and Treatment of Valvular Heart Disease David Messika-Zeitoun Disclosures

CT MRI

Juergens Radiology 2004

Left Ventricular Volumes and Ejection Fraction

Page 55: Diagnosis and treatment of valvular heart disease.assets.escardio.org/assets/presentations/EE2012/48.pdfDiagnosis and Treatment of Valvular Heart Disease David Messika-Zeitoun Disclosures

Comprehensive Evaluation

Aortic Valve Area Coronary arteries Ejection fraction

Page 56: Diagnosis and treatment of valvular heart disease.assets.escardio.org/assets/presentations/EE2012/48.pdfDiagnosis and Treatment of Valvular Heart Disease David Messika-Zeitoun Disclosures

Mitral

Stenosis

Page 57: Diagnosis and treatment of valvular heart disease.assets.escardio.org/assets/presentations/EE2012/48.pdfDiagnosis and Treatment of Valvular Heart Disease David Messika-Zeitoun Disclosures

Mitral Valve Area

29 patients

Sinus Rhythm

MVAECHO :

1.44±0.53 cm2

(0.7- 2.3)

Early diastole

Page 58: Diagnosis and treatment of valvular heart disease.assets.escardio.org/assets/presentations/EE2012/48.pdfDiagnosis and Treatment of Valvular Heart Disease David Messika-Zeitoun Disclosures

MVA – Experienced Operator

0.6

0.8

1.0

1.2

1.4

1.6

1.8

2.0

2.2

2.4

2.6

0.6 0.8 1.0 1.2 1.4 1.6 1.8 2 2.2 2.4 2.6

MV

A-C

T (

cm

2)

MVA-ECHO (cm2)

Dif

fere

nc

e (

MV

A-C

T,

MV

A-E

CH

O)

(cm

2)

Mean (MVA-CT, MVA-ECHO) (cm2)

-1.0

-0.8

-0.6

-0.4

-0.2

0.0

0.2

0.4

0.6

0.8

1.0

0.6 0.8 1.0 1.2 1.4 1.6 1.8 2.0 2.2 2.4 2.6

Messika-Zeitoun, JACC 2006

Page 59: Diagnosis and treatment of valvular heart disease.assets.escardio.org/assets/presentations/EE2012/48.pdfDiagnosis and Treatment of Valvular Heart Disease David Messika-Zeitoun Disclosures

Examples

Page 60: Diagnosis and treatment of valvular heart disease.assets.escardio.org/assets/presentations/EE2012/48.pdfDiagnosis and Treatment of Valvular Heart Disease David Messika-Zeitoun Disclosures

MVA – Non-experienced Operator

MV

A, cm

2

CT

non-experienced

CT

experienced

2D

experienced

1.45±0.55 1.47±0.49 1.38±0.52

P = 0.25

P=0.70

1.10

1.20

1.30

1.40

1.00

1.50

0.6

0.8

1

1.2

1.4

1.6

1.8

2

2.2

2.4

2.6

2.8

0.6 0.8 1 1.2 1.4 1.6 1.8 2 2.2 2.4 2.6 2.8

MV

A-C

T (

cm

2)

MVA-ECHO (cm2)

Page 61: Diagnosis and treatment of valvular heart disease.assets.escardio.org/assets/presentations/EE2012/48.pdfDiagnosis and Treatment of Valvular Heart Disease David Messika-Zeitoun Disclosures

Work in

Progress

Page 62: Diagnosis and treatment of valvular heart disease.assets.escardio.org/assets/presentations/EE2012/48.pdfDiagnosis and Treatment of Valvular Heart Disease David Messika-Zeitoun Disclosures

Alkhadi, Radiology 2005

Mitral Insufficiency

Page 63: Diagnosis and treatment of valvular heart disease.assets.escardio.org/assets/presentations/EE2012/48.pdfDiagnosis and Treatment of Valvular Heart Disease David Messika-Zeitoun Disclosures

Aortic Insufficiency

Alkhadi, Radiology 2005

Page 64: Diagnosis and treatment of valvular heart disease.assets.escardio.org/assets/presentations/EE2012/48.pdfDiagnosis and Treatment of Valvular Heart Disease David Messika-Zeitoun Disclosures

Limits

Image Quality

Exclusion of patients in AF

Reference method debatable: semi-quantitative echocardiography

or angiography

Thresholds

FEUCHTNER AJR 2008 Alkhadi, Radiology 2007

Page 65: Diagnosis and treatment of valvular heart disease.assets.escardio.org/assets/presentations/EE2012/48.pdfDiagnosis and Treatment of Valvular Heart Disease David Messika-Zeitoun Disclosures

Prosthetic Valves

Page 66: Diagnosis and treatment of valvular heart disease.assets.escardio.org/assets/presentations/EE2012/48.pdfDiagnosis and Treatment of Valvular Heart Disease David Messika-Zeitoun Disclosures

Infective Endocarditis

Page 67: Diagnosis and treatment of valvular heart disease.assets.escardio.org/assets/presentations/EE2012/48.pdfDiagnosis and Treatment of Valvular Heart Disease David Messika-Zeitoun Disclosures

Conclusion

Calcium Scoring in patients in low gradient low ejection fraction

TAVI

Aortic Valve Area

CT coronary angiography

Ejection fraction

Mitral valve area

Mitral and aortic insufficiency , Prosthesis, Infective

endocarditis?

Seconde Line Examination

First Line Examination

Page 68: Diagnosis and treatment of valvular heart disease.assets.escardio.org/assets/presentations/EE2012/48.pdfDiagnosis and Treatment of Valvular Heart Disease David Messika-Zeitoun Disclosures

Thank You